

Carlos Guijarro Herraiz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1501057/carlos-guijarro-herraiz-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94 papers	3,567 citations	22 h-index	58 g-index
143 ext. papers	4,517 ext. citations	5.6 avg, IF	5 L-index

#	Paper	IF	Citations
94	Symptoms Experienced at the Acute Phase of SARS-CoV-2 Infection as Risk Factor of Long-term Post-COVID Symptoms: The LONG-COVID-EXP-CM Multicenter Study.. <i>International Journal of Infectious Diseases</i> , 2022 ,	10.5	4
93	Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey. <i>Clinica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2022 , 34, 10-10	0.3	
92	Exploring the Recovery Curve for Gastrointestinal Symptoms from the Acute COVID-19 Phase to Long-term Post-COVID: The LONG-COVID-EXP-CM Multicenter Study.. <i>Journal of Medical Virology</i> , 2022 ,	19.7	0
91	Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2021 ,	1.4	2
90	La albuminuria y la enfermedad polivascular mejoran la capacidad predictiva de los modelos multivariados despu3 de un evento cardiovascular agudo. Cohorte AIRVAG. <i>Revista Clinica Espanola</i> , 2021 , 222, 138-138	0.7	1
89	Recomendaciones para mejorar el control lip3dico en pacientes en prevenci3n primaria. Documento de consenso de la Sociedad Espa3la de Cardiolog3a. <i>REC: CardioClinics</i> , 2021 , 56, 118-128	0.2	2
88	SARS-CoV-2 reinfection in a closed setting: lessons for the community. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 675-677	35.1	1
87	LDL cholesterol and atherosclerosis: The evidence. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2021 , 33 Suppl 1, 25-32	1.4	2
86	Validation of the QMon-20 oscillometric blood pressure monitor for professional office use in the general population according to the ANSI/ESH/ISO 81060-2:2018 protocol. <i>Blood Pressure Monitoring</i> , 2021 , 26, 393-395	1.3	
85	Prevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study. <i>Lung</i> , 2021 , 199, 249-253	2.9	14
84	SARS-CoV-2 new infections among health-care workers after the first dose of the BNT162b2 mRNA COVID-19 vaccine. A hospital-wide cohort study. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1699.e1-1699.e4	9.5	7
83	External validation of the European and American equations for calculating cardiovascular risk in a Spanish working population. <i>Revista Clinica Espanola</i> , 2021 , 221, 561-568	0.5	
82	Impact of Previous Coronavirus Disease 2019 on Immune Response After a Single Dose of BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab299	1	9
81	Recommendations to improve lipid control in primary prevention patients. A consensus document of the Spanish Society of Cardiology. <i>REC: CardioClinics</i> , 2021 , 56, 208-217	0.2	2
80	Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. <i>New England Journal of Medicine</i> , 2021 , 384, 497-511	59.2	1158
79	Comprehensive management of risk factors in peripheral vascular disease. Expert consensus. <i>Revista Clinica Espanola</i> , 2021 , 222, 82-82	0.5	0
78	Similar prevalence of long-term post-COVID symptoms in patients with asthma: A case-control study. <i>Journal of Infection</i> , 2021 , 83, 237-279	18.9	3

77	Long-term post-COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study. <i>Journal of Infection</i> , 2021 , 83, 237-279	18.9	11
76	Diabetes and the Risk of Long-term Post-COVID Symptoms. <i>Diabetes</i> , 2021 , 70, 2917-2921	0.9	5
75	Fatigue and Dyspnoea as Main Persistent Post-COVID-19 Symptoms in Previously Hospitalized Patients: Related Functional Limitations and Disability. <i>Respiration</i> , 2021 , 1-10	3.7	7
74	Anxiety, depression and poor sleep quality as long-term post-COVID sequelae in previously hospitalized patients: A multicenter study. <i>Journal of Infection</i> , 2021 , 83, 496-522	18.9	13
73	Sustained low-density lipoprotein-cholesterol. <i>European Journal of Clinical Investigation</i> , 2021 , e13732	4.6	0
72	How primordial magnetic fields shrink galaxies. <i>Monthly Notices of the Royal Astronomical Society</i> , 2020 , 495, 4475-4495	4.3	12
71	Delphi-based recommendations for the management of cardiovascular comorbidities in patients with psoriatic arthritis and moderate-to-severe psoriasis. <i>Rheumatology International</i> , 2020 , 40, 969-981	3.6	3
70	Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU). <i>Clínica E Investigación En Arteriosclerosis</i> , 2020 , 32, 183-192	1.4	0
69	Hospital-Wide SARS-CoV-2 seroprevalence in health care workers in a Spanish teaching hospital. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020 ,	0.9	12
68	PCSK9 inhibitors: Ratification of the role of LDL cholesterol in cardiovascular prevention. Towards a convergence of European and North American prevention guidelines?. <i>Revista Clínica Española</i> , 2020 , 220, 374-382	0.7	1
67	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 325-332	4	
66	Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach. <i>JAMA Cardiology</i> , 2020 , 5, 1452-1453	16.2	
65	Evaluating the efficacy of an Advanced Care Planning Program for Health Decisions in patients with advanced heart failure: protocol for a Randomized Clinical Trial. <i>BMC Cardiovascular Disorders</i> , 2020 , 20, 456	2.3	1
64	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019 , 31, 128-139	1.4	13
63	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. <i>Atherosclerosis</i> , 2019 , 287, 89-92	3.1	20
62	Probiotic Yogurt for the Prevention of Antibiotic-associated Diarrhea in Adults: A Randomized Double-blind Placebo-controlled Trial. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, 717-723	3	5
61	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2019 , 31, 128-139	0.3	
60	Standards for global cardiovascular risk management arteriosclerosis. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019 , 31 Suppl 1, 1-43	1.4	1

59	Letter by Guijarro Regarding Article, "Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis". <i>Stroke</i> , 2018 , 49, e169	6.7	0
58	Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2018 , 30, 240-247	1.4	
57	PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity. <i>JAMA Cardiology</i> , 2017 , 2, 1168-1169	16.2	4
56	Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain. <i>Advances in Therapy</i> , 2015 , 32, 944-61	4.1	24
55	Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target. <i>Medicina Clinica (English Edition)</i> , 2015 , 145, 67-69	0.3	
54	Recomendaciones de la gu1a para el diagn3stico y tratamiento del aneurisma de aorta abdominal. <i>Angiologia</i> , 2015 , 67, 297-303	0	2
53	Effects on intestinal microbiota of probiotic fermented milk used for prevention of antibiotic-associated diarrhoea. <i>European Food Research and Technology</i> , 2012 , 235, 1199-1206	3.4	4
52	Differences in the use of health resources by Spanish and immigrant HIV-infected patients. <i>Enfermedades Infecciosas Y Microbiolog1a Clinica</i> , 2012 , 30, 458-62	0.9	4
51	Device closure for stroke with patent foramen ovale. <i>New England Journal of Medicine</i> , 2012 , 366, 2322; author reply 2323-4	59.2	4
50	Prevalence and Characteristics of Lipid Abnormalities in Patients Treated With Statins in Primary and Secondary Prevention in Spain. DYSIS-Spain Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011 , 64, 286-294	0.7	0
49	Enfermedad arterial oclusiva en los estudios REACH, FRENA y AIRVAG. <i>Annals of Vascular Surgery</i> , 2009 , 23, 21-27		0
48	A simple prognostic score for risk assessment in patients with acute pancreatitis. <i>European Journal of Internal Medicine</i> , 2009 , 20, e43-8	3.9	18
47	Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 50, 148-52	3.1	90
46	In search of lost time: age, CVD, and intensive statin treatment. <i>Lancet, The</i> , 2008 , 372, 535	40	0
45	Thyroid hormone resistance and pituitary enlargement after thyroid ablation in a woman on levothyroxine treatment. <i>Thyroid</i> , 2008 , 18, 1119-23	6.2	2
44	Secondary prevention of arterial disease in very elderly people: results from a prospective registry (FRENA). <i>Angiology</i> , 2008 , 59, 427-34	2.1	9
43	Peripheral arterial disease is a marker of risk for abdominal aortic aneurysms in patients with coronary artery disease. <i>American Journal of Cardiology</i> , 2006 , 97, 1549-50	3	7
42	Decisiones al final de la vida: suspensi3n de antibi3ticos en presencia de infecci3n activa. <i>Revista Espanola De Geriatria Y Gerontologia</i> , 2006 , 41, 297-300	1.7	3

41	Mortality among adult patients admitted to the hospital on weekends. <i>European Journal of Internal Medicine</i> , 2006 , 17, 322-4	3.9	86
40	Enfermedad arterial periférica desconocida en pacientes con síndrome coronario agudo: prevalencia y patrón diferencial de los factores de riesgo cardiovascular tradicionales y emergentes. <i>Revista Española De Cardiología</i> , 2005 , 58, 1403-1410	1.5	24
39	Occult vascular lesions in patients with atherothrombotic events: the AIRVAG cohort. <i>European Journal of Vascular and Endovascular Surgery</i> , 2005 , 30, 57-62	2.3	11
38	Severe polycythemia as the first clinical presentation of hepatopulmonary syndrome. <i>Journal of Clinical Gastroenterology</i> , 2003 , 37, 89-91	3	6
37	Cardiovascular disease after renal transplantation. <i>Kidney International</i> , 2002 , 78-84	9.9	55
36	Assessing clinical probability of organic disease in patients with involuntary weight loss: a simple score. <i>European Journal of Internal Medicine</i> , 2002 , 13, 240-245	3.9	32
35	Transcription factor-kappa B (NF-kappa B) and renal disease. <i>Kidney International</i> , 2001 , 59, 415-24	9.9	374
34	Statins: effects beyond cholesterol lowering. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 1738-41	4.3	39
33	Expenditures for the care of patients with HIV. <i>New England Journal of Medicine</i> , 2001 , 344, 1948-9	59.2	2
32	High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2001 , 104,	16.7	10
31	Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 267, 536-40	3.4	66
30	Elevated liver enzymes following initiation of antiretroviral therapy. <i>JAMA - Journal of the American Medical Association</i> , 2000 , 283, 2526-7	27.4	38
29	The central role of nuclear factor-kappa B in mesangial cell activation. <i>Kidney International</i> , 1999 , 71, S76-9	9.9	46
28	Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis. <i>Kidney International</i> , 1999 , 56, S80-S83	9.9	11
27	Lipophilic statins induce apoptosis of human vascular smooth muscle cells. <i>Kidney International</i> , 1999 , 56, S88-S91	9.9	20
26	Lipid abnormalities in stable liver transplant recipients--effects of cyclosporin, tacrolimus, and steroids. <i>Transplant International</i> , 1998 , 11, 137-42	3	14
25	Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. <i>American Journal of Kidney Diseases</i> , 1998 , 31, 190-4	7.4	71
24	Lipoprotein changes in patients with chronic hepatitis C treated with interferon- α <i>American Journal of Gastroenterology</i> , 1998 , 93, 1901-1904	0.7	2

23	3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. <i>Circulation Research</i> , 1998 , 83, 490-500	15.7	350
22	Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha. <i>American Journal of Gastroenterology</i> , 1998 , 93, 1901-4	0.7	21
21	Increased lipoproteins and fibrinogen in chronic renal allograft dysfunction. <i>American Journal of Nephrology</i> , 1997 , 17, 445-9	4.6	21
20	Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines. <i>Contributions To Nephrology</i> , 1997 , 120, 210-8	1.6	8
19	Isoprenoids, Ras and proliferative glomerular disease. <i>Contributions To Nephrology</i> , 1997 , 120, 219-27	1.6	1
18	Regulation of mesangial cell proliferation by the mevalonate pathway. <i>Contributions To Nephrology</i> , 1997 , 120, 191-6	1.6	6
17	Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. <i>Archives of Internal Medicine</i> , 1997 , 157, 227-232		17
16	Serum albumin and mortality after renal transplantation. <i>American Journal of Kidney Diseases</i> , 1996 , 27, 117-23	7.4	56
15	Lipids and progressive renal failure. <i>Contributions To Nephrology</i> , 1996 , 118, 17-23	1.6	2
14	Expression of leucocyte chemoattractants by interstitial renal fibroblasts: up-regulation by drugs associated with interstitial fibrosis. <i>Clinical and Experimental Immunology</i> , 1996 , 106, 518-22	6.2	45
13	Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. <i>Kidney International</i> , 1996 , 49, 518-24	9.9	247
12	Lovastatin inhibits lipopolysaccharide-induced NF-kB activation in human mesangial cells. <i>Nephrology Dialysis Transplantation</i> , 1996 , 11, 990-996	4.3	15
11	Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. <i>Kidney International</i> , 1995 , 48, 363-71	9.9	52
10	Early glomerular changes in rats with dietary-induced hypercholesterolemia. <i>American Journal of Kidney Diseases</i> , 1995 , 26, 152-61	7.4	75
9	EFFECT OF FENOFIBRATES IN HEART TRANSPLANT PATIENTS. <i>Transplantation</i> , 1995 , 59, 451	1.8	3
8	IMMUNOSUPPRESSIVE EFFECTS OF LEFLUNOMIDE IN EXPERIMENTAL CHRONIC VASCULAR REJECTION. <i>Transplantation</i> , 1995 , 60, 887-890	1.8	2
7	IMMUNOSUPPRESSIVE EFFECTS OF LEFLUNOMIDE IN EXPERIMENTAL CHRONIC VASCULAR REJECTION. <i>Transplantation</i> , 1995 , 60, 887-890	1.8	18
6	Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure. <i>Current Opinion in Nephrology and Hypertension</i> , 1993 , 2, 372-9	3.5	12

5	Neoplasms of Unknown Primary Site: A Clinicopathological Study of Autopsied Patients. <i>Tumori</i> , 1993 , 79, 321-324	1.7	38
4	Visceral leishmaniasis in HIV-infected patients. <i>Aids</i> , 1991 , 5, 1272-1273	3.5	8
3	Acute encephalopathy in adult as delayed presentation of occupational lead intoxication. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989 , 52, 127-8	5.5	1
2	Spontaneous bacterial peritonitis due to <i>Yersinia enterocolitica</i> in secondary alcoholic hemochromatosis. <i>Journal of Clinical Gastroenterology</i> , 1989 , 11, 675-8	3	8
1	Impact of previous COVID-19 on immune response after a single dose of BNT162b2 SARS-CoV-2 vaccine		2